A Study of the Safety and Efficacy of Venetoclax for Participants With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical Practice

Recruiting

Brief Summary: This observational study will evaluate the safety and effectiveness of Venetoclax used in routine clinical practice for participants diagnosed with chronic lymphocytic leukemia (CLL).

Recruitment & Eligibility

Inclusion Criteria

Participants diagnosed with chronic lymphocytic leukemia who have been prescribed Venetoclax for the first time according to the approved label
Participants (and/or legal representative) who voluntarily agree to participate in this study and sign informed consent

Exclusion Criteria

-Participants with contraindications to venetoclax as listed on the approved local label

Primary Outcome Measures

Name	Time	Method
Number of Participants With Adverse Events	Up to Approximately 7 Years	An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. For more details on adverse events please see the Adverse Event section.

Secondary Outcome Measures

Name	Time	Method
Overall Response	Up to Approximately 7 Years	Overall Response will be assessed by the physician in charge of the study in accordance with the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines.

Locations (13): Inje University - Busan Paik Hospital /ID# 233882
🇰🇷
Busan, Busan Gwang Yeogsi, Korea, Republic of
Pusan National University Hospital /ID# 216850
🇰🇷
Busan, Busan Gwang Yeogsi, Korea, Republic of
Kyungpook National University Hospital /ID# 233884
🇰🇷
중구, Daegu Gwang Yeogsi, Korea, Republic of
The catholic university of korea st. Paul's hospital /ID# 238907
🇰🇷
Seoul, Gyeonggido, Korea, Republic of
Ajou University Hospital /ID# 249512
🇰🇷
Suwon-si, Gyeonggido, Korea, Republic of
Chonnam National University Hwasun Hospital /ID# 216849
🇰🇷
Hwasun-gun, Jeonranamdo, Korea, Republic of
Korea University Anam Hospital /ID# 216851
🇰🇷
Seoul, Seoul Teugbyeolsi, Korea, Republic of
Seoul National University Hospital /ID# 216853
🇰🇷
Seoul, Seoul Teugbyeolsi, Korea, Republic of
Samsung Medical Center /ID# 217180
🇰🇷
Seoul, Seoul Teugbyeolsi, Korea, Republic of
The Catholic University of Korea, Seoul St. Marys Hospital /ID# 216852
🇰🇷
Seoul, Seoul Teugbyeolsi, Korea, Republic of
The Catholic University of Korea, Seoul St. Marys Hospital /ID# 217181
🇰🇷
Seoul, Seoul Teugbyeolsi, Korea, Republic of
The Catholic University of Korea, Yeouido ST. Mary's Hospital /ID# 217179
🇰🇷
Seoul, Seoul Teugbyeolsi, Korea, Republic of
Yonsei University Health System Severance Hospital /ID# 215348
🇰🇷
Seoul, Korea, Republic of